September 19, 2024ScienceOpen Access

Targeting cancer with small-molecule pan-KRAS degraders

View Full Paper

Ask AI

Bookmark

Degradation of oncogenic KRAS alleles kills diverse mutant cancer cells while sparing normal cells, yielding profound and sustained pathway modulation across treated models.
A heterobifunctional small molecule potently degrades 13 out of 17 prevalent oncogenic KRAS alleles, whereas conventional covalent inhibitors primarily target the single G12C variant.
Biophysical and structural studies of ternary complexes enabled targeted degradation that induced tumor regression in vivo—murine models; further clinical translation is needed.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates tumor regression and potent degradation of oncogenic KRAS alleles in cancer models, highlighting a therapeutic strategy beyond covalent inhibitors.

Cite This Study

Popow et al. (2024) studied this question.

synapsesocial.com/papers/68e57fadb6db64358751d16c https://doi.org/10.1126/science.adm8684

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates tumor regression and potent degradation of oncogenic KRAS alleles in cancer models, highlighting a therapeutic strategy beyond covalent inhibitors.

Targeting cancer with small-molecule pan-KRAS degraders

Key Points

Discussion

Implication

Cite This Study

Targeting cancer with small-molecule pan-KRAS degraders

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider